Magnesium silicate

Identification

Generic Name
Magnesium silicate
DrugBank Accession Number
DB13249
Background

Magnesium silicate is a compound of magnesium oxide and silicon. It is the magnesium salt of silicic acid containing an unspecified amount of water. The molecular formula can be expressed more clearly as MgSiO3.xH2O.1 It is known as talc and it presents many uses in the cosmetic industry, food industry and pharmaceutical industry.2 Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.3

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 100.387
Monoisotopic: 99.9467121
Chemical Formula
MgO3Si
Synonyms
Not Available

Pharmacology

Indication

Magnesium silicate is used to absorb moisture, prevent caking, and to improve the feel of a product. In the pharmaceutical companies, it is used as a dietary supplement, as part of the formulation ingredients in drug production, in antacid and antiulcer preparations, as a component of antiepileptic drugs, in antifungal topical agents and in the treatment of acne and as a facial moisturizer.2

When complexed with arginine, magnesium silicate can be used as an antiatherosclerotic agent and to promote bone and cartilage formation in mammals.1

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

As a supplement, magnesium silicate acts by replacing the factor that is missing. In the case of antacids, it is a non-absorbable antacid whose main activity is related to the absorption of hydrochloric acid. More specifically, magnesium silicate acts as a neutralizing and astringent agent.5

Absorption

Orally administered magnesium silicate is rapidly neutralized in the stomach and it forms magnesium chloride and silicon dioxide. From the modified portion, some of the formed magnesium is absorbed.1 The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5

Volume of distribution

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5

Protein binding

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5

Metabolism

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5

Route of elimination

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5

Half-life

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5

Clearance

The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

The administration of more than 50 meq of magnesium daily can produce the development of hypermagnesemia. This can provoke the formation of bladder and renal calculi. There is no known toxicity and the LD50 in animals are higher than 500 mg/kg in humans.1 It is determined that magnesium silicate is not carcinogenic.4

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetaminophenMagnesium silicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetophenazineMagnesium silicate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium silicate.
AlfacalcidolThe serum concentration of Magnesium silicate can be increased when it is combined with Alfacalcidol.
AlimemazineMagnesium silicate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Formula ECMagnesium silicate (12.5 mg / tab) + Calcium carbonate (250 mg / tab) + Cupric sulfate (0.5 mg / tab) + Ergocalciferol (100 unit / tab) + Magnesium oxide (125 mg / tab) + Manganese sulfate (2.5 mg / tab) + Pyridoxine hydrochloride (2.5 mg / tab) + Zinc sulfate (3.75 mg / tab)TabletOralBody Wise International LlcNot applicableNot applicableCanada flag

Categories

ATC Codes
A02AA05 — Magnesium silicate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal organides
Sub Class
Alkaline earth metal oxides
Direct Parent
Alkaline earth metal oxides
Alternative Parents
Metalloid salts / Inorganic salts / Inorganic oxides
Substituents
Alkaline earth metal oxide / Inorganic metalloid salt / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
9B9691B2N9
CAS number
1343-88-0
InChI Key
ZADYMNAVLSWLEQ-UHFFFAOYSA-N
InChI
InChI=1S/Mg.3O.Si/q+2;3*-2;+4
IUPAC Name
silicon(4+) ion magnesium(2+) ion trioxidandiide
SMILES
[O--].[O--].[O--].[Mg++].[Si+4]

References

General References
  1. Rashid I., Nidal H. Daraghmeh M., Omari A., Babur Z., Chowdhry S., Leharne H., Adnan A. (2011). Profiles of drug substances and related methodology. Academic Press. [ISBN:978-0-12-387667-6]
  2. FDA Ingredients [Link]
  3. FDA code of federal regulations [Link]
  4. Toxnet [Link]
  5. Lecture [File]
ChemSpider
32698785
RxNav
1310566
Wikipedia
Talc
MSDS
Download (47.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentBurning Mouth Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)1910 ºC'MSDS'
water solubilityInsolubleMonograph
Predicted Properties
PropertyValueSource
logP-0.65Chemaxon
pKa (Strongest Acidic)15.7Chemaxon
pKa (Strongest Basic)-1.8Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area0 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity13.11 m3·mol-1Chemaxon
Polarizability0.95 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 23, 2017 20:38 / Updated at January 09, 2021 18:41